BRAF and melanoma: Because PLK1 has already been shown to contribute to melanoma progression and poorer outcomes in general [63,66,67,74,75], we specifically focused on the relevance of PLK1 in BRAF-mutated melanoma and further investigated whether it may serve as a therapeutic target to overcome BRAFi resistance.